Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.45 |
| ▸ | IDH2 | P48735 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | TGM1 | P22735 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30409940 | 1.00 | IDH1 (0.45) | IDH1IDH2SYKHCRTR1CCNK | |
| SCHEMBL30700819 | 0.85 | SYK (0.50) | IDH1IDH2SYKHCRTR1CCNK | |
| SCHEMBL31308805 | 0.85 | SYK (0.50) | IDH1IDH2SYKHCRTR1CCNK | |
| SCHEMBL23292323 | 0.83 | CCNK (0.55) | IDH1IDH2SYKCCNKCDK12 | |
| SCHEMBL28545982 | 0.83 | CCNK (0.55) | IDH1IDH2SYKCCNKCDK12 | |
| SCHEMBL22895357 | 0.83 | CCNK (0.55) | IDH1IDH2SYKCCNKCDK12 | |
| SCHEMBL31308764 | 0.81 | GPR119 (0.50) | GPR119 | |
| SCHEMBL30700787 | 0.81 | GPR119 (0.50) | GPR119 | |
| SCHEMBL25260355 | 0.80 | GPR119 (0.41) | IDH1IDH2SYKGPR119 | |
| SCHEMBL30409580 | 0.80 | GPR119 (0.39) | IDH1IDH2HCRTR1GPR119HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4416154-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-08-21 | — | — | EP | disclosed |
| CN-118103374-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | IDH1 292/4885IDH2 530/4885SYK 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.